UNCY
Unicycive Therapeutics, Inc.
Next earnings Aug 12, 2026 · consensus $-0.37 EPS
Last earnings +2.8% on 2026-05-12
$7.92
▼ -1.25%$8.02▲ +16.74%
over 1Y
L $3.74EODHDH $8.56
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today-1.2%
1W+11.9%
1M+13.6%
3M+25.5%
YTD+38.3%
1Y+16.7%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy
Conservative balance sheet (liabilities/equity 0.63x); but revenue fell -29.0% YoY.
Unicycive Therapeutics, Inc. shows $675K in FY2023 revenue (-29.0% YoY), a -3934.1% net margin, and -87.9% ROE.
Sources: SEC EDGAR (CIK 0001766140, latest 10-Q filed 2026-05-12) · EODHD · as of 6/24/2026, 5:31:04 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.